Life Sciences Daily Summary: What Happened on October 14, 2026

BioNTech’s BNT113 misses progression-free survival endpoint

BNT113 plus pembrolizumab did not significantly improve progression-free survival over pembrolizumab alone in the AHEAD-MERIT Phase 2/3 trial.12 The trial tests the combination as an initial treatment for certain people with HPV16-positive head and neck cancer.1

Progression-free survival was one of the trial’s two primary endpoints, and the data monitoring committee recommended continuing the study to assess overall survival, the other primary endpoint.2 Under the planned statistical design, a significant overall-survival benefit could still count as a positive trial outcome.2 BNT113 is an off-the-shelf messenger RNA vaccine encoding HPV16 proteins intended to prompt T cells to attack cancer cells.1

MHRA sets out UK regulatory plans through 2030

The Medicines and Healthcare products Regulatory Agency published a strategy covering medicines, medical devices, clinical research and AI-enabled health technologies through 2030.3 The agency plans to expand its use of real-world data and AI analysis to identify possible safety issues sooner.3

For a higher-tier scientific-advice service, the MHRA aims to cut its turnaround from 90 days to 45 days.3 It also plans to halve the initial assessment target for qualifying Phase 1 trials to 14 days, establish a center focused on AI and digital health, and publish an action plan on AI in medicines development in 2027.3 The strategy includes plans to increase diversity in clinical studies and introduce a Women’s Health Plan during the year.3

Soufflé raises $135 million for three programs

Soufflé Therapeutics secured $135 million to advance three drug candidates toward clinical testing.4 The programs target facioscapulohumeral muscular dystrophy, or FSHD, heart failure, and muscle and metabolic disorders.4

Pfizer and Enodia team up on Sec61 inhibitors

Pfizer and Enodia Therapeutics agreed to discover and develop small-molecule inhibitors of Sec61, a cellular protein channel involved in producing other proteins.57 Enodia will lead early discovery work across multiple targets, and Pfizer is set to take over clinical trials, manufacturing, regulatory submissions and commercialization after that phase.58

The agreement could be worth more than $500 million, including an upfront payment, research and development milestones, sales milestones and royalties.578 Enodia’s internal Sec61 pipeline focuses mainly on immunology, oncology and inflammation, with possible applications in virology.5

Zealand puts $30 million upfront into AI-designed obesity drug research

Zealand Pharma will pay Generate Biomedicines $30 million at the outset to research protein medicines for obesity and other metabolic diseases.6 The deal covers two initial research programs and gives Zealand an option to add a third.6

Generate may receive up to $35 million in early preclinical milestones and nearly $1.2 billion in total milestone payments, plus tiered royalties.6 Generate will lead research through candidate selection, after which Zealand will handle clinical development, regulatory submissions and commercialization worldwide.6